ReviewNutrients2022
Liver Metastatic Breast Cancer: Epidemiology, Dietary Interventions, and Related Metabolism.
Review in Nutrients, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it, 22 citations in OpenAlex.
- TACE Versus TARE in the Treatment of Liver-Metastatic Breast Cancer: A Systematic Review.Tomography (Ann Arbor, Mich.) · 2025Pooled it
- Impact of Underlying Liver Disease on the Risk and Prognostic Factors of Breast Cancer Liver Metastases: A Retrospective Multicenter Cohort Study.Cancer medicine · 2026Article
- Factors determining survival in oligometastatic breast cancer in a retrospective cohort study from a low and middle income country.Scientific reports · 2026Article
- Breast cancer liver metastases and the impact of receptor expression on survival.Clinical & experimental metastasis · 2026Article
- Case Report: Liver Metastasis from Ductal Carcinoma In Situ of the Breast.International medical case reports journal · 2026Article
- Plasma small-extracellular vesicles' proteomic signature in neoadjuvant chemotherapy-naïve breast cancer patients.PloS one · 2026Article
- Review
- Research advances in treatment strategies for breast cancer liver metastases: A comprehensive review.iLIVER · 2025Review
- Clinicopathological Perspectives of Liver Mass Biopsies: A Single Center Experience of 406 Cases.Archives of Iranian medicine · 2025Article
- Utility of circulating tumor DNA in secondary liver malignancies: What we know and what is to come.Journal of surgical oncology · 2025Review
- Impact of targeting the platelet-activating factor and its receptor in cancer treatment.Military Medical Research · 2025Review
- Co-targeting of metabolism using dietary and pharmacologic approaches reduces breast cancer metastatic burden.NPJ breast cancer · 2025Article
- Symptomatic bone marrow metastasis in triple-negative breast cancer: a case report and literature review.Frontiers in oncology · 2025Article
- Article
- Oligometastatic Breast Cancer: Seeking the Cure by Redefining Stage IV Disease?Current treatment options in oncology · 2024Review
- Altered lipid metabolism as a predisposing factor for liver metastasis in MASLD.Molecules and cells · 2024Review
- The Age-Male-Albumin-Bilirubin-Platelets (aMAP) Risk Score Predicts Liver Metastasis Following Surgery for Breast Cancer in Chinese Population: A Retrospective Study.ImmunoTargets and therapy · 2024Article
- Complete response after treatment of breast cancer with isolated liver metastasis: a case report.AME case reports · 2024Article
- Assessment of the albumin-bilirubin score in breast cancer patients with liver metastasis after surgery.Heliyon · 2023Article
- Risk factors and survival prediction of young breast cancer patients with liver metastases: a population-based study.Frontiers in endocrinology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The median overall survival of patients with metastatic breast cancer is only 2-3 years, and for patients with untreated liver metastasis, it is as short as 4-8 months. Improving the survival of women with breast cancer requires more effective anti-cancer strategies, especially for metastatic disease. Nutrients can influence tumor microenvironments, and cancer metabolism can be manipulated via a dietary modification to enhance anti-cancer strategies. Yet, there are no standard evidence-based recommendations for diet therapies before or during cancer treatment, and few studies provide definitive data that certain diets can mediate tumor progression or therapeutic effectiveness in human cancer. This review focuses on metastatic breast cancer, in particular liver metastatic forms, and recent studies on the impact of diets on disease progression and treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.